skip to main content
Idioma:

Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial

FUDIM, MARAT ; CYR, DEREK D. ; WARD, JONATHAN H. ; HERNANDEZ, ADRIAN F. ; LEPAGE, SERGE ; MORROW, DAVID A. ; SHARMA, KAVITA ; CLAGGETT, BRIAN L. ; STARLING, RANDALL C. ; VELAZQUEZ, ERIC J. ; WILLIAMSON, KRISTIN M. ; DESAI, AKSHAY S. ; ZIEROTH, SHELLEY ; SOLOMON, SCOTT D. ; BRAUNWALD, EUGENE ; MENTZ, ROBERT J.

Journal of cardiac failure, 2024-05 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
  • Título:
    Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial
  • Autor: FUDIM, MARAT ; CYR, DEREK D. ; WARD, JONATHAN H. ; HERNANDEZ, ADRIAN F. ; LEPAGE, SERGE ; MORROW, DAVID A. ; SHARMA, KAVITA ; CLAGGETT, BRIAN L. ; STARLING, RANDALL C. ; VELAZQUEZ, ERIC J. ; WILLIAMSON, KRISTIN M. ; DESAI, AKSHAY S. ; ZIEROTH, SHELLEY ; SOLOMON, SCOTT D. ; BRAUNWALD, EUGENE ; MENTZ, ROBERT J.
  • Assuntos: heart failure with mildly reduced ejection fraction ; Heart failure with preserved ejection fractions ; systolic blood pressure ; worsening heart failure
  • É parte de: Journal of cardiac failure, 2024-05
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsartan alone, despite more symptomatic hypotension (SH). Concern about SH may be limiting the use of sacubitril/valsartan in appropriate patients. We characterized patients by the occurrence of SH (investigator-reported) after randomization to either sacubitril/valsartan or valsartan. A key trial inclusion criterion was systolic blood pressure (SBP) ≥ 100 mmHg for the preceding 6 hours and no SH. We also compared outcomes based on baseline SBP stratified by the median blood pressure. The primary endpoint was time-averaged proportional change in NT-proBNP levels from baseline through weeks 4 and 8. A secondary hierarchical outcome (win ratio) consisted of: (1) cardiovascular death; (2) hospitalizations due to HF; (3) urgent HF visits; and (4) change in NT-proBNP levels. Among 466 randomized patients, 92 (19.7%) experienced SH (sacubitril/valsartan, n = 56 [24.0%]; valsartan, n = 36 [15.5%]; P = 0.020). The median time to the first SH event was similar between treatment arms (18 days vs 15 days, respectively; P = 0.42) as was the proportion of first SH events classified as serious by investigators. Patients who experienced SH with sacubitril/valsartan were more likely to be white (OR 1.87 [95% CI: 0.31, 11.15]), to have a lower baseline SBP (per 10 mmHg increase, OR 0.68 [95% CI: 0.55, 0.85]), or to have a left ventricular ejection fraction (LVEF) of > 60% (OR 2.21 [95% CI: 1.05, 4.65]). Time-averaged change in NT-proBNP levels did not differ between patients with baseline SBP ≥ 128 mmHg vs SBP < 128 mmHg (interaction, P = 0.43). The composite hierarchical outcome for sacubitril/valsartan in patients with baseline SBP ≥ 128 mmHg had a win ratio of 1.34 ([95% CI: 0.91, 1.99]; P = 0.096) vs SBP < 128 mmHg with a win ratio of 1.09 ([95%CI: 0.73, 1.66]; P = 0 .62; interaction P value = 0.42). Among patients with LVEF > 40% stabilized after WHF, incident SH was more common with sacubitril/valsartan compared with valsartan. SH was associated with lower baseline SBP, being white, and having higher LVEF. Treatment benefits with sacubitril/valsartan may be more pronounced in patients with higher baseline SBP and lower LVEF (≤ 60%). (Funded by Novartis Pharmaceutical Corporation; ClinicalTrials.gov number, NCT03988634.)
  • Editor: Elsevier Inc
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  6 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.